Drugs / DNV001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07391722 | Feb 2026 → Jun 2027 expected | hyperlipoproteinemia | Hangzhou Dinovate Biotech Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DNV001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07391722 ↗ |
| Modality | Monoclonal antibody | “human monoclonal antibody” NCT07391722 ↗ |
| Route | Subcutaneous | “administered as a sterile solution for subcutaneous injection.” NCT07391722 ↗ |